Perfil molecular em genes cyp3a4 e cyp2j2: um caminho para a farmacogenética do Rivaroxaban em uma população do Norte do Brasil

In recent years, new anticoagulants have been developed with the purpose of minimizing the difficulties encountered in the clinical management of conventional dru- gs, but there are no published data on its pharmacogenetics. Considering the hypothe- sis that polymorphisms related to its metabolism may be the source of genetic variability, this study aims to make inferences on molecular epidemiology of polymorphisms in CyP3a4 (rs2246709) and CyP2j2 (rs890293) genes related to the metabolism of Rivaroxaban, a new direct factor Xa inhibitor. 136 samples from healthy individuals in a population of northern Brazil with a high degree of inter-ethnic mix, so as to guarantee that the pharmacogenetic goal was achieved, have been subjected to a parallel analysis of genomic ancestry for the individuals investigated. The results sho- wed significant differences among genotypes for CyP3a4 observed in the study com- pared to all ancestral populations for a polymorphism 99,365,719 a> G ( P G (P